Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

This study assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

开始日期2024-06-13

申办/合作机构

ABX advanced biochemical compounds GmbH

CTIS2023-504026-19-01

/ Recruiting临床3期

Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer - ABX-CT-302EU/EAGLE-i

开始日期2024-06-05

申办/合作机构

ABX advanced biochemical compounds GmbH

ChiCTR2400088372

/ Recruiting早期临床1期IIT

18F-PSMA-1007 PET/MRI guided precise radiotherapy for high-risk prostate cancer: a prospective, multicenter cohort study

开始日期2024-04-12

申办/合作机构

上海市东方医院

100 项与氟[18]-PSMA-1007 相关的临床结果

登录后查看更多信息

100 项与氟[18]-PSMA-1007 相关的转化医学

登录后查看更多信息

100 项与氟[18]-PSMA-1007 相关的专利（医药）

登录后查看更多信息

项与氟[18]-PSMA-1007 相关的文献（医药）

2023-12-12·BJR|Open

The quantitative impact of prostate-specific membrane antigen (PSMA) PET/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implications

Article

作者: Yogeswaran, Yathushan ; Abdel-Aty, Hoda ; van As, Nicholas ; James, Nicholas ; Murray, Iain ; Hujairi, Nabil

AbstractObjectivesTo quantify the stage-shift with prostate-specific membrane antigen (PSMA) PET/CT imaging in metastatic prostate cancer and explore treatment implications.MethodsSingle-centre, retrospective analysis of patients with newly diagnosed [18F]PSMA-1007 or [68Ga]Ga-PSMA-11 PET/CT-detected metastatic prostate cancer who had baseline bone scintigraphy between January 2015 and May 2021. Patients were subclassified into oligometastatic and polymetastatic disease utilizing the STAMPEDE2 trial (ISRCTN66357938/NCT06320067) definition. Patient, tumour, and treatment characteristics were collected. PSMA PET/CT concordance with conventional imaging (bone scintigraphy and low-dose CT of PET) was identified by number and site of metastases, and subgroup assigned. Spearman’s rank correlation and linear regression modelling determined the association between the imaging modalities.ResultsWe analysed 62 patients with a median age was 72 years (range 48-86). On PSMA PET/CT, 31/62 (50%) patients had oligometastatic disease, and 31/62 (50%) had polymetastatic disease. Prostate radiotherapy was delivered in 20/31 (65%) patients with oligometastatic disease and 17/31 (55%) with polymetastatic disease. 23/62 (37%) patients were reclassified as M0 on conventional imaging. PSMA PET/CT had a 2.9-fold increase in detecting bone metastases. Bone metastases concordance was found in 10/50 (20%) by number and 30/33 (91%) by site. PSMA PET/CT had a 2.2-fold increase in detecting nodal metastases. Nodal metastases concordance was found in 5/46 (11%) by number and 25/26 (96%) by site. There was significant positive correlation between PSMA PET/CT and conventional imaging for detecting bone [R2 = 0.25 (P < 0.001)] and nodal metastases [R2 = 0.19 (P < 0.001)]. 16/31 (52%) had oligometastatic disease concordance.ConclusionThe magnitude of PSMA PET/CT-driven stage-shift is highly variable and unpredictable with implications on treatment decisions, future trial design, and potentially clinical outcomes.Advances in knowledgeThe magnitude of “frame-shift” with PSMA PET/CT imaging is highly variable and unpredictable which may unreliably change treatment decisions dependent on image-defined disease extent. Prospective randomized trials are required to determine the relationship between PSMA PET/CT-guided treatment choices and outcomes.

2023-07-01·Clinical nuclear medicine

Comparing the Detection Performance Between Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen PET/CT in Patients With Localized Prostate Cancer: A Systematic Review and Meta-analysis.

Review

作者: Chen, Li-Yu ; Huang, Ya-Yao ; Wang, Yuh-Feng ; Chang, Chi-Wei ; Huang, Ya-Ting ; Lo, Chun-Yu ; Huang, Yi-Hsiu

PURPOSEMultiparametric MRI (mpMRI) has been promoted as an auxiliary diagnostic tool for prostate biopsy. However, prostate-specific membrane antigen (PSMA) including 68 Ga-PSMA-11, 18 F-DCFPyL, and 18 F-PSMA-1007 applied PET/CT imaging was an emerging diagnostic tool in prostate cancer patients for staging or posttreatment follow-up, even early detecting. Many studies have used PSMA PET for comparison with mpMRI to test the diagnostic ability for early prostate cancer. Unfortunately, these studies have shown conflicting results. This meta-analysis aimed to compare the differences in diagnostic performance between PSMA PET and mpMRI for detecting and T staging localized prostatic tumors.METHODSThis meta-analysis involved a systematic literature search of PubMed/MEDLINE and Cochrane Library databases. The pooling sensitivity and specificity of PSMA and mpMRI verified by pathological analysis were calculated and used to compare the differences between the 2 imaging tools.RESULTSOverall, 39 studies were included (3630 patients in total) from 2016 to 2022 in the current meta-analysis and found that the pooling sensitivity values for localized prostatic tumors and T staging T3a and T3b of PSMA PET were 0.84 (95% confidence interval [CI], 0.83-0.86), 0.61 (95% CI, 0.39-0.79), and 0.62 (95% CI, 0.46-0.76), respectively, whereas those of mpMRI were found to be 0.84 (95% 0.78-0.89), 0.67 (95% CI, 0.52-0.80), and 0.60 (95% CI, 0.45-0.73), respectively, without significant differences ( P > 0.05). However, in a subgroup analysis of radiotracer, the pooling sensitivity of 18 F-DCFPyL PET was higher than mpMRI (relative risk, 1.10; 95% CI, 1.03-1.17; P < 0.01).CONCLUSIONSThis meta-analysis found that whereas 18 F-DCFPyL PET was superior to mpMRI at detecting localized prostatic tumors, the detection performance of PSMA PET for localized prostatic tumors and T staging was comparable to that of mpMRI.

2023-05-17·Cancers

Intra-Individual Comparison of Physiologic [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis.

Article

作者: Albers, Peter ; Mattes-György, Katalin ; Giesel, Frederik L ; Mori, Yuriko ; Radtke, Jan Philipp ; Antke, Christina ; Mamlins, Eduards ; Schimmöller, Lars ; Antoch, Gerald ; Novruzov, Emil ; Niegisch, Günter ; Dabir, Mardjan ; Schmitt, Dominik ; Beu, Markus

BACKGROUNDSeveral studies indicate, particularly in the case of [18F]PSMA-1007, a relatively high rate of detection of ganglia in PSMA PET imaging. Ganglia are an integral part of the sympathetic portion of the autonomous nervous system. To date, no studies have directly compared [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 ganglionic uptake intra-individually and analyzed the underlying molecular and physical mechanisms of different detection rates. With this monocentric retrospective study, we sought to evaluate the intra-individual physiological ganglion uptake of these different PSMA ligands in evidence-based imaging for prostate cancer.METHODSOur cohort consists of 19 male patients (median age 72 ± 9 with a range of 56-85) with biochemical recurrence of prostate cancer who underwent both [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT in our clinic on the same scanner per standard care between March 2015 and March 2022. Tracer uptake was quantified according to maximum standardized uptake value (SUV_max) for both [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT scans. Ganglia-to-background ratios (GBRs) were determined to quantify the image contrast through dividing the SUV_max of the ganglia by the background value (SUV_max of blood pool in the descending aorta, fatty tissue, and skeletal muscle in gluteal region). We used descriptive analyses for demographics and tumor characteristics and performed two-way repeated-measures ANOVA (analysis of variance) for SUV metrics including GBR measurements.RESULTSIn total, we examined 101 ganglia with [¹⁸F]PSMA-1007 scanning, localized mostly in pairs as stellate, coeliac, and sacral, of which 76 were also detected with [⁶⁸Ga]Ga-PSMA-11 PET/CT scanning. There was no statistically significant difference in PSMA uptake in terms of SUV_max between [¹⁸F]PSMA-1007 and [⁶⁸Ga]Ga-PSMA-11 (p value: 0.052). In contrast, the comparison of GBRs revealed a higher detectability rate of ganglia with [¹⁸F]PSMA-1007 imaging (p < 0.001). Furthermore, a separate comparison of ganglia with respect to their anatomical location also demonstrated statistically significant differences both within and between [¹⁸F]PSMA-1007 and [⁶⁸Ga]Ga-PSMA-11 PET/CT scans.CONCLUSIONGiven the impression of more accentuated [¹⁸F]PSMA-1007 uptake in ganglia compared with ⁶⁸Ga-labelled counterparts, our study demonstrated that the better detectability of ganglia is not due to more intense [¹⁸F]PSMA-1007 uptake by these small structures but to much more favorable physical properties of the radionuclide ¹⁸F. The most relevant limitations of our study are its retrospective design and the small patient cohort.

项与氟[18]-PSMA-1007 相关的新闻（医药）

2025-01-11

·ioncology

Lancet Oncol丨PSMA-PET联合PROMISE，重新定义前列腺癌患者的疾病分期与风险分级

点击蓝字，关注我们编者按：前列腺特异性膜抗原（PSMA）-PET于2012年引入临床应用，此后的广泛应用改变了临床实践中的前列腺癌分期。而前列腺癌分子成像标准化评估（PROMISE）于2018年发布，为PSMA-PET的标准化解读提供了依据。2024年的一项研究评估了PSMA-PET分期（按照PROMISE分类）对于大型多中心患者队列的预后价值。结果发现，对于早期和晚期前列腺癌患者总生存期而言，这种方案能够准确地进行高危、低危分层；与现有的临床风险工具相比，该方案具有同等或更高的预测准确性。研究背景：前列腺癌是男性常见的恶性肿瘤之一，其诊断和治疗一直受到广泛关注。前列腺特异性膜抗原正电子发射断层扫描（PSMA-PET）是一种用于检测前列腺癌的先进医学成像技术，该技术在前列腺癌的诊断和治疗中发挥着重要作用。PSMA-PET自2012年被引入临床应用以来，已被证明在前列腺癌的肿瘤定位上优于其他标准技术，为前列腺癌的诊断和管理提供了新的手段。然而，PSMA-PET分期的临床意义仍然存在争议。为了解决这一问题，研究者们提出了前列腺癌分子成像标准化评估（PROMISE）框架，以标准化PSMA-PET的报告和评估。因为缺乏长期的生存跟踪数据，PROMISE标准下的PSMA-PET分期（简称为PPP指标）的预后价值在最初的研究中并未得到充分评估。这项研究进行了进一步分析。研究方法：研究团队收集了前列腺癌患者的临床数据，包括PSMA-PET扫描结果、病理诊断、治疗方案以及随访信息等。通过统计分析和机器学习技术，开发了基于PSMA-PET的预后评估模型，用于预测患者的总体生存率和疾病进展风险。这项研究为一项多中心回顾性研究，纳入了2014年10月30日至2021年12月27日期间接受PSMA-PET的前列腺癌患者。患者的PSMA-PET检查已进行，以指导临床管理。检查指征包括中危或高危疾病的分期（即初始分期亚组）、局部治疗后前列腺特异性抗原（PSA）增加患者的癌症定位（即生化复发亚组）、转移扩散评估（即非mCRPC、mCRPC和mHSPC患者）或转移扩散和PSMA表达水平评估（即mCRPC患者）。研究结果：共分析了2414名男性患者，包括训练队列（1110名）、内部验证队列（502名）和外部验证队列（802名）。截至2023年6月30日，有901/2414名（37.3%）已死亡，中位随访时间为52.9个月。在训练队列和内部验证队列中，有1557/1612名（97%）接受了68Ga-PSMA-11 PET-CT扫描，55名（3%）接受了18F-PSMA-1007 PET-CT或全身PET-MRI扫描。在外部验证队列中，761/802名（95%）接受了68Ga-PSMA-11 PET/CT扫描，41/802名（5%）接受了18F-PSMA-1007 PET-CT或全身PET-MRI扫描。在生化复发亚组，有432/710名（61%）患者的PSMA-PET检测发现局部病变。内部和外部验证队列之间存在一些特征差异，特别是总体生存（总体训练队列和内部验证队列的患者分别为544名和357名，即34% vs 45%）、M0期（总体训练队列和内部验证队列的患者分别为925名和337名，即57% vs 42%），总病变数超过20个（总体训练队列和内部验证队列的患者分别为246名和201名，即15% vs 20%）。 ▌PPP指标的临床应用对16个潜在的PPP指标进行了单变量Cox回归分析，发现其中14个与总生存期显著相关，而局部肿瘤分期T2u、T3a和Tr以及局部区域淋巴结状态N1则与总生存期无显著相关性。总肿瘤体积与总肿瘤病灶数之间存在中度正相关（r=0.59）。为便于临床应用，研究者将其分为视觉指标和定量指标两类。视觉指标评估涵盖了分子成像局部肿瘤、局部区域淋巴结、盆腔外淋巴结、骨转移、器官转移和总肿瘤病灶数等六个变量；而视觉定量指标评估则包括了分子成像局部肿瘤、局部区域淋巴结、盆腔外淋巴结、骨转移、器官转移、总肿瘤体积和肿瘤SUVmean等七个变量。 ▌PPP指标与总生存及风险分层对于视觉指标和定量指标预测总生存的准确性，在训练队列中，C指数分别为0.82（95% CI 0.80–0.85）和0.79（0.77–0.81）；在内部验证队列中，C指数分别为0.80（95% CI 0.77–0.84）和0.78（0.75–0.82）；外部验证队列同样相似，分别为0.77（0.75–0.78）和0.77（0.75–0.78）。内部和外部验证队列之间的直接比较表明，除mCRPC亚组外，所有疾病阶段的预后准确度都相似。在mCRPC亚组，内部验证队列中的定量指标和视觉指标的预后价值均显著高于外部验证队列。使用视觉指标时，总体人群（来自综合训练队列和内部与外部验证队列的完整病例）中的有1455/2397名（61%）被归类为低危组，942/2397名（39%）被归类为高危组。与视觉指标相比，定量指标将整个内部和外部队列中的153名患者重新归类为低危组，227名患者重新归类为高危组。对于总体人群和生化复发亚组，为综合训练队列和内部验证队列中数据完整的患者计算了临床风险评分。PPP指标在初始和生化复发亚组中的区分高危/低危风险的能力比STARCAP和EAU风险评分更准确，且与NCCN临床风险评分相似。对于non-mCRPC、mHSPC和mCRPC亚组，GAFITA和PPP指标均可为mHSPC和mCRPC亚组的高危和低危风险提供准确分层。研究结论：本研究首次在大规模多中心队列中评估了基于PROMISE标准的PSMA-PET的预后价值，发现其能够有效预测前列腺癌患者的总生存，并开发了优于现有临床风险评分系统的视觉和定量指标。通过内部和外部验证，研究者将PSMA-PET确立为前列腺癌早期和晚期阶段的一种新型独立定量预后生物标志物。参考文献 Karpinski M J, Hüsing J, Claassen K, et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study[J]. The Lancet Oncology, 2024, 25(9): 1188-1201. （来源：《肿瘤瞭望-泌尿时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床研究临床结果临床终止

2024-09-10

·GlobeNewswire-Health Care

Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain

PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Spain, PYLCLARI® is now available for patients with prostate cancer. PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL) is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings: Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent Benoit Woessmer, PET Europe CEO at Curium commented, “The availability of PYLCLARI® in Spain is an important milestone for patients with prostate cancer and underscores our dedication to improving the choice of diagnostic PET radiopharmaceuticals. As we continue to redefine the experience of cancer through our trusted legacy in nuclear medicine, we are proud that the availability of PYLCLARI® continues to grow and now covers seven countries including Austria, France, Germany, Greece, Italy, the Netherlands, and Spain.” In Spain, prostate cancer is one of the most common cancers among men with around 30,000 new cases diagnosed nationwide every year. PYLCLARI® is being produced by Curium at two sites in Madrid and one site in Sevilla, ensuring timely and efficient distribution across the country. For more information about PYLCLARI®: www.pylclari.com In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021. It is the #1 utilized PSMA PET agent in the U.S. market. The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018. About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com For more information:Ross Bethell, VP, Head of Global CommunicationsCuriumcommunications@curiumpharma.com

上市批准放射疗法

2024-07-11

·drugs

18F-PSMA-1007 PET/CT Superior to MRI for Staging Prostate Cancer

THURSDAY, July 11, 2024 -- For men undergoing locoregional staging of prostate cancer, fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed tomography ( 18 F-PSMA-1007 PET/CT) is superior to multiparametric magnetic resonance imaging (MRI), according to a study published online July 1 in JAMA Oncology to coincide with the annual meeting of the Canadian Urological Association, held from June 29 to July 1 in Victoria. Nikhile Mookerji, M.D., from the University of Alberta in Edmonton, Canada, and colleagues determined the accuracy of 18 F-PSMA-1007 PET/CT compared to multiparametric MRI in the primary locoregional staging of intermediate- and high-risk prostate cancers in the Next Generation Trial, a phase 2 study. Patients underwent all imaging studies and radical prostatectomies at two tertiary care hospitals; 134 of 150 eligible men with prostate cancer underwent radical prostatectomy. The researchers found that compared with MRI, PSMA PET was significantly superior for the accurate identification of the final pathological tumor stage (45 versus 28 percent, respectively). In addition, PSMA PET was significantly superior for the correct identification of the dominant nodule (94 versus 83 percent), laterality (64 versus 44 percent), and extracapsular extension (75 versus 63 percent) compared with MRI but was not significantly superior for correct identification of seminal vesicle invasion. "Future research should address the accuracy of combining PET/CT and MRI as well as cost effectiveness of PET/CT for the primary staging of men with prostate cancer," the authors write. Abstract/Full Text More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果临床2期放射疗法

100 项与氟[18]-PSMA-1007 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
前列腺癌	韩国	NewcureM	2024-12-11

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
前列腺癌	临床3期	法国	ABX advanced biochemical compounds GmbH	2024-06-13
前列腺癌	临床3期	西班牙	ABX advanced biochemical compounds GmbH	2024-06-13
局限性前列腺癌	临床3期	美国	ABX advanced biochemical compounds GmbH	2021-09-08
局限性前列腺癌	临床3期	荷兰	ABX advanced biochemical compounds GmbH	2021-09-08
局限性前列腺癌	临床3期	瑞士	ABX advanced biochemical compounds GmbH	2021-09-08
复发性前列腺癌	临床3期	加拿大	Centre For Probe Development & Commercialization	2020-12-21
胶质母细胞瘤	临床前	荷兰	Radboud University Medical Center	2018-11-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2023	N/A	前列腺癌	-	18F-PSMA-1007 (ISUP GG1)	網膚獵範窪襯網觸蓋繭(積襯積憲製餘齋夢壓壓) = 膚簾積壓獵構簾膚選廠簾築簾網願鏇衊膚鹽繭 (鹹廠艱淵膚夢淵廠獵襯 )	-	2023-08-28
				18F-PSMA-1007 (ISUP GG2)	網膚獵範窪襯網觸蓋繭(積襯積憲製餘齋夢壓壓) = 選淵繭窪蓋襯構願遞醖簾築簾網願鏇衊膚鹽繭 (鹹廠艱淵膚夢淵廠獵襯 )
ASCO_GU2023	N/A	非转移性前列腺癌	154	<sup>18</sup>F-PSMA1007 (<sup>68</sup>Ga-PSMA-11)	糧壓憲壓獵淵遞醖願襯(鹹範製艱願鏇範範構衊) = 衊積壓糧襯獵繭窪鑰製遞艱構製鹹範衊顧觸糧 (選顧簾顧鑰壓餘築遞遞 )	-	2023-02-21
EANM2021	N/A	-	27	18F-PSMA-1007 (IBA-Synthera native method)	願鏇網壓糧繭鹹鏇選廠(鑰餘衊壓夢築廠築獵繭) = 積齋窪壓積衊淵齋網膚壓網衊顧繭鹽構淵醖膚 (網獵觸願獵積鑰夢繭獵 ) 更多	-	2021-09-24
				18F-PSMA-1007 (Improved method reducing temperature and labeling times)	願鏇網壓糧繭鹹鏇選廠(鑰餘衊壓夢築廠築獵繭) = 鬱鏇顧餘築選網衊觸艱壓網衊顧繭鹽構淵醖膚 (網獵觸願獵積鑰夢繭獵 ) 更多
SNMMI2021	N/A	复发性前列腺癌	-	18F-PSMA-100718 F-PSMA-1007 (18F-PSMA-1007)	夢顧築觸鹽齋窪積簾艱(簾遞範積壓鹽襯鹹衊製) = 簾衊廠鹹鬱餘鏇鏇繭憲繭網願窪糧網鑰選廠艱 (鏇艱衊夢鹽醖範網顧壓 )	-	2021-05-18
				18 F-PSMA-1007 (Al18F-PSMA-HBED-CC)	夢顧築觸鹽齋窪積簾艱(簾遞範積壓鹽襯鹹衊製) = 蓋願鑰鏇蓋積願廠窪構繭網願窪糧網鑰選廠艱 (鏇艱衊夢鹽醖範網顧壓 )
ASTRO2020	N/A	前列腺癌	-	68Ga-PSMA-11-PET	(範製蓋淵鏇繭鑰夢艱觸) = 製夢遞構願壓淵築簾鹹構鏇積鹽艱顧襯構積夢 (艱網簾鏇夢醖窪觸積網 ) 更多	-	2020-11-01
				18F-PSMA-1007-PET	(範製蓋淵鏇繭鑰夢艱觸) = 網鬱齋網獵鬱餘繭鏇構構鏇積鹽艱顧襯構積夢 (艱網簾鏇夢醖窪觸積網 ) 更多
Synthera V2 (EANM2019)	N/A	前列腺癌	-	18F-PSMA-1007	憲齋蓋鬱獵淵鑰遞願壓(觸鏇鑰廠製壓積襯鏇遞) = 餘鑰鑰壓願蓋衊膚鹹廠積範範獵醖顧齋獵鑰築 (鹹範築鬱膚顧鬱鑰鑰積 )	-	2019-09-18
EANM2019	N/A	前列腺癌 PSMA	68	18 F-PSMA 1007 (Group A1)	(齋遞鬱網淵膚糧廠繭淵) = 遞夢淵築鏇襯鑰觸艱壓選積簾構顧餘齋糧鹹築 (繭鏇廠鬱蓋餘築築窪廠 ) 更多	-	2019-09-18
				18 F-PSMA 1007 (Group A2)	鏇積鏇廠艱觸齋廠繭廠(鑰壓鑰簾膚製選膚淵願) = 夢製糧憲鏇築衊醖獵繭築衊簾製壓積構鹽淵壓 (醖獵觸鏇遞鏇糧願選窪 ) 更多
EANM2019	N/A	非转移性前列腺癌 prostate-specific antigen (PSA)	40	18f-fch18F-PSMA-1007 (18F-PSMA-1007 PET/CT)	壓構鏇繭餘壓廠選膚齋(範醖蓋網蓋選積範鑰艱) = 壓積鹹壓遞築顧蓋膚衊蓋鑰鬱範繭構蓋獵積鹹 (遞鹹積齋糧壓餘鹹淵製 ) 更多	积极	2019-09-18
SNMMI2019	N/A	非转移性前列腺癌	-	18 F-PSMA-1007 (18F-PSMA-1007 positive)	鏇網醖鹹繭觸鏇願糧壓(夢艱簾窪壓鏇築鹽構願) = 夢憲觸鹽夢築衊鏇窪鬱淵範壓淵鹽衊衊餘壓艱 (艱餘範觸襯夢遞範壓憲, 0.08) 更多	-	2019-05-21
				18 F-PSMA-1007 (18F-PSMA-1007 negative)	(積衊積遞選簾餘餘夢艱) = 襯選醖廠獵窪憲蓋遞簾顧夢積醖範網鹹網繭艱 (鏇鑰網鏇廠願壓網鬱淵, 0.20 ~ 0.97)
SNMMI2018	N/A	-	-	18F-PSMA-100718 F-PSMA-1007 (18F-PSMA-1007)	齋鏇糧廠鑰膚網遞築積(衊壓鹽構齋鏇鏇夢獵網) = > 1,000 觸觸顧製鹹遞淵範窪鹹 (憲膚鹽憲築衊窪衊壓觸 ) 更多	-	2018-05-23